Saltar al contenido
Merck
Todas las fotos(3)

Key Documents

View All Documentation

901855

Sigma-Aldrich

(S,R,S)-AHPC-PEG5-Alkyne

Sinónimos:

(2S,4R)-1-((S)-2-(tert-Butyl)-4-oxo-7,10,13,16,19-pentaoxa-3-azadocos-21-ynoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, Crosslinker−E3 Ligase ligand conjugate, Protein degrader building block for PROTAC® research, Template for synthesis of targeted protein degrader

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(3)

About This Item

Fórmula empírica (notación de Hill):
C36H52N4O9S
Peso molecular:
716.88
UNSPSC Code:
51171641
NACRES:
NA.22

ligand

VH032

form

solid

reaction suitability

reaction type: click chemistry
reagent type: ligand-linker conjugate

functional group

alkyne

storage temp.

2-8°C

SMILES string

O=C(CCOCCOCCOCCOCCOCC#C)N[C@H](C(N1[C@H](C(NCC2=CC=C(C3=C(C)N=CS3)C=C2)=O)C[C@@H](O)C1)=O)C(C)(C)C

Application

Protein degrader builiding block (S,R,S)-AHPC-PEG5-Alkyne enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a von Hippel-Lindau (VHL)-recruiting ligand and a PEGylated crosslinker with pendant alkyne for click chemistry with an azide on the target ligand. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and PROTAC, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks with a pendant alkyne group, parallel synthesis can be used to more quickly generate PROTAC libraries that feature variation in crosslinker length, composition, and E3 ligase ligand.

Automate your VHL-PEG based PROTACs with Synple Automated Synthesis Platform (SYNPLE-SC002)

Other Notes

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Portal: Building PROTAC® Degraders for Targeted Protein Degradation

Targeted Protein Degradation by Small Molecules

Small-Molecule PROTACS: New Approaches to Protein Degradation

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Impact of linker length on the activity of PROTACs

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

related product

Referencia del producto
Descripción
Precios

901490

(S,R,S)-AHPC hydrochloride, ≥97%

901487

(S,S,S)-AHPC hydrochloride, ≥97%

901488

(S,R,S)-AHPC-PEG2-NH2 hydrochloride, ≥95%

901493

(S,R,S)-AHPC-PEG1-NH2 hydrochloride, ≥95%

901494

N-Methylated pomalidomide, ≥98%

901495

Pomalidomide-PEG3-NH2 hydrochloride, ≥95%

901496

Pomalidomide-C6-CO2H, ≥98%

901500

Pomalidomide-C3-CO2H, ≥95%

901503

(S,R,S)-AHPC-PEG1-Alkyne, ≥95%

901511

(S,R,S)-AHPC-PEG3-NH2 hydrochloride, ≥95%

901504

Pomalidomide-PEG3-CO2H, ≥95%

901517

(S,R,S)-AHPC-PEG2-Alkyne, ≥95%

901516

Pomalidomide-PEG1-NH2 hydrochloride, ≥95%

901513

Pomalidomide-PEG2-NH2 hydrochloride, ≥95%

901523

Pomalidomide-PEG1-Alkyne, ≥98%

901533

(S,R,S)-AHPC-PEG3-Alkyne, ≥95%

901534

(S,R,S)-AHPC-C6-CO2H hydrochloride

901531

Pomalidomide-PEG3-Alkyne, ≥95%

901529

Pomalidomide-PEG2-Alkyne, ≥95%

901527

Pomalidomide-PEG1-CO2H, ≥95%

901526

Pomalidomide-PEG2-CO2H, 95%

901525

Pomalidomide-C9-CO2H, ≥95%

901558

Lenalidomide, ≥95%

901835

Pomalidomide-PEG6-Alkyne

901834

Pomalidomide-PEG5-Alkyne, ≥95%

901833

Pomalidomide-PEG4-Alkyne

901832

Pomalidomide-PEG6-NH2 hydrochloride, ≥98%

901831

Pomalidomide-PEG5-NH2 hydrochloride

901830

Pomalidomide-PEG4-NH2 hydrochloride, ≥95%

901829

Pomalidomide-PEG6-CO2H

901828

Pomalidomide-PEG5-CO2H, ≥95%

901824

Pomalidomide-PEG4-CO2H

901860

(S,R,S)-AHPC-PEG6-NH2 hydrochloride, ≥95%

901851

(S,R,S)-AHPC-PEG4-Alkyne

901850

(S,R,S)-AHPC-PEG5-NH2 hydrochloride

901848

(S,R,S)-AHPC-PEG4-NH2 hydrochloride, ≥95%

901873

(S,R,S)-AHPC-PEG6-Alkyne

903434

Pomalidomide-PEG6-butyl azide, ≥95%

903442

Pomalidomide-PEG6-butyl iodide, ≥95%

903833

Pomalidomide-PEG2-azide

903825

Pomalidomide-PEG1-azide

903957

(S,R,S)-AHPC-PEG1-azide

904651

(S,R,S)-AHPC-PEG3-azide, ≥95%

904724

Pomalidomide-PEG2-butyl iodide, ≥95%

904708

Pomalidomide-C6-PEG3-butyl iodide, ≥95%

904678

Pomalidomide-PEG3-azide

904686

Pomalidomide-C6-PEG3-butyl azide, ≥95%

904813

(S,R,S)-AHPC-PEG2-azide

904821

(S,R,S)-AHPC-C6-PEG3-butyl azide, ≥95%

904880

Pomalidomide-C6-PEG1-C3-PEG1-butyl azide, ≥95%

904872

Pomalidomide-PEG2-butyl azide, ≥95%

904864

(S,R,S)-AHPC-PEG6-butyl azide, ≥95%

905178

(S,R,S)-AHPC-C6-PEG1-C3-PEG1-butyl azide, ≥95%

905275

(S,R,S)-AHPC-PEG6-butyl amine hydrochloride, ≥95%

905216

(S,R,S)-AHPC-PEG2-butyl azide, ≥95%

905232

(S,R,S)-AHPC-C6-PEG3-butyl amine hydrochloride, ≥95%

905224

Pomalidomide-PEG6-butyl amine hydrochloride, ≥95%

905208

Pomalidomide-C6-PEG3-butyl amine hydrochloride, ≥98%

905399

(S,R,S)-AHPC-PEG2-butyl chloride

905380

(S,R,S)-AHPC-C6-PEG3-butyl chloride, ≥95%

905402

(S,R,S)-AHPC-C6-PEG1-C3-PEG1-butyl chloride, 95%

906050

Pomalidomide-C6-PEG1-C3-PEG1-butyl iodide, ≥95%

906123

(S,R,S)-AHPC-PEG2-butyl amine hydrochloride

907677

(S,R,S)-AHPC-PEG6-butyl chloride

909378

(S,R,S)-AHPC-PEG6-Azide, ≥95%

909386

Pomalidomide-PEG4-Azide, ≥95%

909394

Pomalidomide-PEG5-azide, ≥95%

909408

Pomalidomide-PEG6-azide, ≥95%

909262

(S,R,S)-AHPC-PEG4-Azide, ≥95%

910007

20-Azido-3,6,9,12,15,18-hexaoxaicosanoic acid, 95%

910015

17-Azido-3,6,9,12,15-pentaoxaheptadecanoic acid, ≥95%

910449

Pomalidomide-PEG2-butyl CO2H, ≥95%

910600

(S,R,S)-AHPC-PEG2-butyl CO2H, ≥95%

910619

Pomalidomide-PEG6-butyl alkyne, ≥95%

910597

(S,R,S)-AHPC-PEG6-butyl alkyne, ≥95%

910554

(S,R,S)-AHPC-PEG6-butyl CO2H, ≥95%

910546

(S,R,S)-AHPC-C6-PEG3-butyl alkyne, ≥95%

910538

(S,R,S)-AHPC-PEG2-butyl alkyne, ≥95%

910511

Pomalidomide-C6-PEG3-butyl alkyne, ≥95.0%

910503

Pomalidomide-PEG2-butyl alkyne, ≥95%

910481

Pomalidomide-PEG6-butyl CO2H, ≥95%

911003

Pomalidomide-PEG2-butyl amine hydrochloride, ≥95%

911801

AHPC-C6-PEG1-C3-PEG1-butyl amine hydrochloride, ≥90%

911690

C5 Lenalidomide, ≥95%

911666

Pomalidomide-C6-NH2 hydrochloride, ≥95%

911658

Pomalidomide-C3-NH2 hydrochloride, ≥95%

911763

C5 Lenalidomide-PEG1-piperazine hydrochloride, ≥95%

913987

Pomalidomide-C6-PEG1-C3-PEG1-butyl amine hydrochloride, ≥95%

915572

Pomalidomide-dipiperazine-NH2 hydrochloride, ≥95%

916536

Pomalidomide-piperazine-pyridine-alkyne-NH2 hydrochloride

917729

C5 Lenalidomide-piperazine-pyridine-alkyne-NH2 hydrochloride, ≥95%

917303

C5 Lenalidomide-C6-PEG1-C3-PEG1-Butyl NH2 hydrochloride, ≥95%

917818

(S,R,S)-AHPC-C9-NH2 hydrochloride, ≥95%

919462

CCW16-PEG5-BocNH, ≥95%

918687

(S,R,S)-AHPC-alkyne-piperidine hydrochloride

919969

C5 Lenalidomide-PEG2-Butyl NH2 hydrochloride, ≥95%

919896

C5 Lenalidomide-dipiperazine-NH2 hydrochloride

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Kedra Cyrus et al.
Molecular bioSystems, 7(2), 359-364 (2010-10-06)
Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can

Artículos

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico